The US investment firm Bioluminescence Ventures (BLV) has emerged from stealth with $477 million to finance biotech companies developing first-in-class or best-in-class disease treatments.
The Indian contract research development and manufacturing organization (CRDMO) Aragen Life Sciences will invest $30 million in building a 160,000 square-meter biologics manufacturing facility in Bangalore.
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the pharmaceutical and healthcare industry around the world to advance discoveries and deliver groundbreaking treatments to patients.
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health products and global clinical supply services. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply.